1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Medical specialties
GeneReach Biotechnology Corp.

GeneReach Biotechnology Corp.

TTPEX:4171
17.00
TWD
-0.10
(-0.58%)
-0.80EPS
963.73MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
2.23
2.96
3.07
3.09
3.2
3.86
6.7
14.92
17.61
13.05
3.92
3.59
4.08
4.16
Basic EPS, GAAP
-1.35
-0.67
-0.51
-0.8
-0.99
0.59
1.41
4.48
6.55
3.85
-2.89
-2.07
-1.93
-0.75
Free Cash Flow per Basic Share
-0.86
-0.36
-0.18
0.01
-0.17
0.07
-0.46
1.83
5.8
5.35
-1.05
-0.55
-0.44
-0.04
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
2.5
3.64
1.2
0.28
- -
- -
Book Value per Share
5.22
7.47
6.97
6.29
5.16
5.89
9.67
14.15
18.27
18.58
14.48
12.48
10.24
10.07
Tangible Book Value per Share
4.56
7.01
6.61
6.02
4.96
5.72
9.53
14
18.1
18.42
14.27
12.26
9.97
9.82
Basic Weighted Avg Shares
43
45
49
49
49
49
55
57
57
57
57
57
57
57
Sales/Revenue/Turnover
96
134
149
150
155
187
366
857
1,012
750
225
206
233
238
Operating Margin (%)
-60.33
-31.62
-18.07
-17.75
-13.78
6.81
31.15
41.7
48.16
32.03
-92.19
-65.8
-37.34
-24.93
Depreciation Expense
21
21
22
20
16
14
26
52
60
65
69
75
71
61
Net Income, GAAP
-58
-30
-25
-39
-48
29
77
257
377
221
-166
-119
-110
-43
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
11.23
22.19
21.07
20.15
- -
- -
- -
- -
Profit Margin (%)
-60.52
-22.77
-16.64
-25.73
-30.97
15.24
21.1
30.02
37.21
29.51
-73.75
-57.5
-47.38
-18.1
Working Capital
68
179
122
150
-57
60
312
554
902
685
426
355
283
280
LT Debt
133
115
94
189
- -
- -
72
129
305
124
98
85
72
66
Total Equity
224
363
339
306
251
311
593
858
1,088
1,103
862
725
597
581
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
14.85
30.37
28.43
12.49
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
9.7
28.93
30.44
15.43
- -
- -
- -
- -
Return on Common Equity (%)
-22.93
-10.36
-7.07
-12
-17.3
10.59
18.28
37.6
40.44
20.91
-17.5
-15.33
-16.92
-7.26

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
154
151
154
LT Borrowings
- -
- -
- -
LT Finance Leases
72
68
66
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
57
57
57
Market Capitalization
1,077
1,080
964

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
484
481
479
Cash, Cash Equivalents & STI
405
406
396
Accounts Receivable, Net
39
33
32
Inventories
33
33
42
Total Current Liabilities
201
192
199
Payables & Accruals
- -
- -
- -
ST Debt
154
151
154
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
10.44%
-5.45%
-17.75%
Free Cash Flow
-359.11%
4.33%
-20.63%
Net Income, GAAP
11.87%
-41.14%
-7.12%
Sales/Revenue/Turnover
18.08%
-14.69%
12.71%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
46
43
62
55
206
2025
52
54
53
72
233
2026
52
60
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.35
-0.63
-0.47
-0.62
-2.07
2025
-0.18
-1.16
-0.65
0.05
-1.93
2026
-0.09
-0.07
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.28
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Hsiao-Fen Chang
Full Time Employees
120
Sector
Health technology
Industry
Medical specialties
Address
Central Science Park Taichung TX Taiwan 407
IPO Date
Nov 19, 2012
Website
genereach.com
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
GeneReach Biotechnology Corp. is a biotechnology company primarily engaged in the research, development, manufacture, and sales of molecular diagnostics products. The company's main products include nucleic acid detection reagents, medical DNA/RNA extraction kits, real-time PCR instruments, and automated nucleic acid extraction instruments. It serves markets in clinical diagnostics, animal health, food safety, and agricultural biotechnology. The company operates primarily in Taiwan and China, with its headquarters located in Taichung, Taiwan. Founded in 2002, GeneReach provides comprehensive molecular diagnostic solutions, including testing kits for infectious diseases, genetic mutations, and foodborne pathogens. In the last 1-2 years, GeneReach Biotechnology Corp. has focused on expanding its strategic collaborations and product portfolios, particularly emphasizing the development and launch of advanced automation solutions for nucleic acid extraction to improve efficiency and throughput. The company has also strengthened its presence in the global molecular diagnostics market through new partnerships and enhancements in its real-time PCR product lines, targeting broader applications in human and veterinary diagnostics. These efforts reflect a strategic shift toward integrating automated testing platforms and expanding its footprint in both clinical and agricultural markets to address growing demand for rapid, reliable molecular testing solutions. GeneReach operates in the biotechnology sector with business segments including molecular diagnostics reagents and instrumentation, targeting hospitals, laboratories, research institutions, and agricultural enterprises. It offers a range of branded products designed for PCR-based testing, gene mutation detection, infectious disease identification, and pathogen screening. The company is a key player in the Asia-Pacific region, leveraging its technological expertise and manufacturing capabilities to serve a diverse customer base across healthcare and food safety industries. GeneReach Biotechnology Corp. is publicly traded under the ticker 4171.TWO and continues to invest in innovation to support growth in the molecular diagnostics field.